Combinations of Drugs in the Treatment of Obesity

Pharmaceuticals

Bruno Halpern¹  Eduardo S. L. Oliveira¹  André M. Faria¹  Alfredo Halpern¹  Maria Edna de Melo¹  Cintia Cercato¹ 

[1]Obesity & Metabolic Syndrome Group, Discipline of Endocrinology & Metabolism, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, 7º andar, sala 7037, 05403-000 - São Paulo, SP, Brazil

[2] E-Mails:

关键词: drug combination;    phentermine;    fenfluramine;    ephedrine;    caffeine;    sibutramine;    orlistat;    metformin;    bupropion;    naltrexone;    zonisamide;    topiramate;    pramlintide;    metreleptin;    leptin;    glucagon-like peptide-1;    peptide YY;    5-hydroxytryptophan;    carbidopa;    noradrenergic drugs;    antidepressants;   

DOI  :  10.3390/ph3082398

来源: mdpi

【 摘 要 】

Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.